PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis

Carlo Giovanni Carrera, Paolo Dapavo, Piergiorgio Malagoli, Luigi Naldi, Luisa Arancio, Francesca Gaiani, Colin Gerard Egan, Marco Di Mercurio, Angelo Cattaneo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Few studies have compared the use of different biologics in a real-life setting in plaque psoriasis patients. Objective: To compare the efficacy of biologics in psoriasis/psoriatic arthritis patients. Methods: Patients treated with adalimumab, etanercept and ustekinumab for at least 16 weeks were included. Achievement of Psoriasis Area Severity Index (PASI), PASI 90/100 response and time taken to achieve PASI 90/100 response were measured. Logistic regression was used to evaluate the effect of psoriasis localization on achievement of PASI 100 response. Results: Two hundred and fifty five patients were included. No difference was observed in PASI 90 response between etanercept and ustekinumab (65.5 vs. 55.4%), while adalimumab-treated patients had a higher response versusustekinumab (71.6 vs. 55.4%, p = .02). More patients achieved complete remission (PASI 100 response) with adalimumab versus etanercept (65.7 vs. 23%, p < .001) or ustekinumab (65.7 vs. 44.6%, p = .003). Adalimumab-treated patients achieving PASI 90 responded more quickly (by three and six months) versus ustekinumab or etanercept. PASI100 response was achieved in ∼43% of adalimumab and ustekinumab treated-patients by three months versus etanercept (14.3%), increasing to 92.5, 85.4 and 35.7%, respectively by six months. PASI100 response was associated with psoriasis nail involvement or genital psoriasis. Conclusion: In the real-life setting, adalimumab was the most effective biological agent for the treatment of plaque psoriasis.

Original languageEnglish
Pages (from-to)481-486
Number of pages6
JournalJournal of Dermatological Treatment
Volume29
Issue number5
DOIs
Publication statusPublished - 2018

Fingerprint

Biological Factors
Psoriasis
Biological Products
Psoriatic Arthritis
Nails
Reaction Time
Adalimumab
Logistic Models
Etanercept
Ustekinumab

Keywords

  • adalimumab
  • biological drugs
  • etanercept
  • Psoriasis
  • psoriatic arthritis
  • ustekinumab

ASJC Scopus subject areas

  • Dermatology

Cite this

PACE study : real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis. / Carrera, Carlo Giovanni; Dapavo, Paolo; Malagoli, Piergiorgio; Naldi, Luigi; Arancio, Luisa; Gaiani, Francesca; Egan, Colin Gerard; Di Mercurio, Marco; Cattaneo, Angelo.

In: Journal of Dermatological Treatment, Vol. 29, No. 5, 2018, p. 481-486.

Research output: Contribution to journalArticle

Carrera, Carlo Giovanni ; Dapavo, Paolo ; Malagoli, Piergiorgio ; Naldi, Luigi ; Arancio, Luisa ; Gaiani, Francesca ; Egan, Colin Gerard ; Di Mercurio, Marco ; Cattaneo, Angelo. / PACE study : real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis. In: Journal of Dermatological Treatment. 2018 ; Vol. 29, No. 5. pp. 481-486.
@article{b132f63528d54cc3b7318cbbd2d5ec99,
title = "PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis",
abstract = "Background: Few studies have compared the use of different biologics in a real-life setting in plaque psoriasis patients. Objective: To compare the efficacy of biologics in psoriasis/psoriatic arthritis patients. Methods: Patients treated with adalimumab, etanercept and ustekinumab for at least 16 weeks were included. Achievement of Psoriasis Area Severity Index (PASI), PASI 90/100 response and time taken to achieve PASI 90/100 response were measured. Logistic regression was used to evaluate the effect of psoriasis localization on achievement of PASI 100 response. Results: Two hundred and fifty five patients were included. No difference was observed in PASI 90 response between etanercept and ustekinumab (65.5 vs. 55.4{\%}), while adalimumab-treated patients had a higher response versusustekinumab (71.6 vs. 55.4{\%}, p = .02). More patients achieved complete remission (PASI 100 response) with adalimumab versus etanercept (65.7 vs. 23{\%}, p < .001) or ustekinumab (65.7 vs. 44.6{\%}, p = .003). Adalimumab-treated patients achieving PASI 90 responded more quickly (by three and six months) versus ustekinumab or etanercept. PASI100 response was achieved in ∼43{\%} of adalimumab and ustekinumab treated-patients by three months versus etanercept (14.3{\%}), increasing to 92.5, 85.4 and 35.7{\%}, respectively by six months. PASI100 response was associated with psoriasis nail involvement or genital psoriasis. Conclusion: In the real-life setting, adalimumab was the most effective biological agent for the treatment of plaque psoriasis.",
keywords = "adalimumab, biological drugs, etanercept, Psoriasis, psoriatic arthritis, ustekinumab",
author = "Carrera, {Carlo Giovanni} and Paolo Dapavo and Piergiorgio Malagoli and Luigi Naldi and Luisa Arancio and Francesca Gaiani and Egan, {Colin Gerard} and {Di Mercurio}, Marco and Angelo Cattaneo",
year = "2018",
doi = "10.1080/09546634.2017.1395805",
language = "English",
volume = "29",
pages = "481--486",
journal = "Journal of Dermatological Treatment",
issn = "0954-6634",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - PACE study

T2 - real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis

AU - Carrera, Carlo Giovanni

AU - Dapavo, Paolo

AU - Malagoli, Piergiorgio

AU - Naldi, Luigi

AU - Arancio, Luisa

AU - Gaiani, Francesca

AU - Egan, Colin Gerard

AU - Di Mercurio, Marco

AU - Cattaneo, Angelo

PY - 2018

Y1 - 2018

N2 - Background: Few studies have compared the use of different biologics in a real-life setting in plaque psoriasis patients. Objective: To compare the efficacy of biologics in psoriasis/psoriatic arthritis patients. Methods: Patients treated with adalimumab, etanercept and ustekinumab for at least 16 weeks were included. Achievement of Psoriasis Area Severity Index (PASI), PASI 90/100 response and time taken to achieve PASI 90/100 response were measured. Logistic regression was used to evaluate the effect of psoriasis localization on achievement of PASI 100 response. Results: Two hundred and fifty five patients were included. No difference was observed in PASI 90 response between etanercept and ustekinumab (65.5 vs. 55.4%), while adalimumab-treated patients had a higher response versusustekinumab (71.6 vs. 55.4%, p = .02). More patients achieved complete remission (PASI 100 response) with adalimumab versus etanercept (65.7 vs. 23%, p < .001) or ustekinumab (65.7 vs. 44.6%, p = .003). Adalimumab-treated patients achieving PASI 90 responded more quickly (by three and six months) versus ustekinumab or etanercept. PASI100 response was achieved in ∼43% of adalimumab and ustekinumab treated-patients by three months versus etanercept (14.3%), increasing to 92.5, 85.4 and 35.7%, respectively by six months. PASI100 response was associated with psoriasis nail involvement or genital psoriasis. Conclusion: In the real-life setting, adalimumab was the most effective biological agent for the treatment of plaque psoriasis.

AB - Background: Few studies have compared the use of different biologics in a real-life setting in plaque psoriasis patients. Objective: To compare the efficacy of biologics in psoriasis/psoriatic arthritis patients. Methods: Patients treated with adalimumab, etanercept and ustekinumab for at least 16 weeks were included. Achievement of Psoriasis Area Severity Index (PASI), PASI 90/100 response and time taken to achieve PASI 90/100 response were measured. Logistic regression was used to evaluate the effect of psoriasis localization on achievement of PASI 100 response. Results: Two hundred and fifty five patients were included. No difference was observed in PASI 90 response between etanercept and ustekinumab (65.5 vs. 55.4%), while adalimumab-treated patients had a higher response versusustekinumab (71.6 vs. 55.4%, p = .02). More patients achieved complete remission (PASI 100 response) with adalimumab versus etanercept (65.7 vs. 23%, p < .001) or ustekinumab (65.7 vs. 44.6%, p = .003). Adalimumab-treated patients achieving PASI 90 responded more quickly (by three and six months) versus ustekinumab or etanercept. PASI100 response was achieved in ∼43% of adalimumab and ustekinumab treated-patients by three months versus etanercept (14.3%), increasing to 92.5, 85.4 and 35.7%, respectively by six months. PASI100 response was associated with psoriasis nail involvement or genital psoriasis. Conclusion: In the real-life setting, adalimumab was the most effective biological agent for the treatment of plaque psoriasis.

KW - adalimumab

KW - biological drugs

KW - etanercept

KW - Psoriasis

KW - psoriatic arthritis

KW - ustekinumab

UR - http://www.scopus.com/inward/record.url?scp=85033708296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033708296&partnerID=8YFLogxK

U2 - 10.1080/09546634.2017.1395805

DO - 10.1080/09546634.2017.1395805

M3 - Article

AN - SCOPUS:85033708296

VL - 29

SP - 481

EP - 486

JO - Journal of Dermatological Treatment

JF - Journal of Dermatological Treatment

SN - 0954-6634

IS - 5

ER -